ºÚÁÏÍø

The patent titled “Chimeric Fibronectin Matrix Mimetics and Uses Thereof” (US 9,072,706) has recently been assigned to the ºÚÁÏÍø with inventors (, , ) and Daniel Roy, Ph.D. (BME PhD 2012 alumnus). The patent relates to a series of recombinant fibronectin peptide mimetics developed to promote wound repair. The technology falls under a new and exciting class of therapies known as wound biologics. The primary commercial application for this technology is to promote healing of hard-to-heal or chronic wounds, including diabetic, venous, and pressure ulcers, which impose a significant health care burden worldwide. Encouraging results from recent studies indicate that topical application of these fibronectin peptide mimetics to full-thickness excisional wounds in diabetic mice accelerates wound closure and promotes granulation tissue deposition, remodeling, and re-vascularization. Denise Hocking is an Associate Professor of Pharmacolog and physiology and of Biomedical Engineering. Daniel Roy is currently a post-doctoral fellow at the US Army Institute of Surgical Research in San Antonio, TX.